Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

No abstract is available for this paper.

• Publication year

  2018

• Venue

  AIDS (London)

• Publication date

  2018-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAD.0000000000001755PMID 29369162PMCID PMC5854536
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy

  2017cited by this paper
• Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX® ADME PGx Panel for Pharmacogenomic Profiling

  2016cited by this paper
• Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing

  2016cited by this paper
• Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

  2016cited by this paper
• Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women

  2015cited by this paper
• Pharmacokinetics of tenofovir during pregnancy and postpartum

  2015cited by this paper
• Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.

  2015cited by this paper
• Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy

  2015cited by this paper
• Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

  2015cited by this paper
• Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing

  2014cited by this paper
• A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.

  2014cited by this paper
• Raltegravir Pharmacokinetics During Pregnancy

  2014cited by this paper
• Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines

  2013cited by this paper
• Lurie Children’s Hospital of Chicago

  2013cited by this paper
• The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women

  2013cited by this paper
• Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

  2012cited by this paper
• The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric Liver

  2011cited by this paper
• Effect of pregnancy on emtricitabine pharmacokinetics

  2011cited by this paper
• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

  2011cited by this paper
• Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

  2011cited by this paper
• Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy

  2010cited by this paper
• Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.

  2009cited by this paper
• In Vivo Glucuronidation Activity of Drugs in Neonates: Extensive Interindividual Variability Despite Their Young Age

  2009cited by this paper
• Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

  2008cited by this paper
• Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics

  2008cited by this paper
• Impact of pregnancy on abacavir pharmacokinetics

  2006cited by this paper
• Reduced lopinavir exposure during pregnancy

  2006cited by this paper
• Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women

  2004cited by this paper
• Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

  2003cited by this paper
• Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, January 7, 2000

  2000cited by this paper
• Guidelines for the use of antiretroviral agents in pediatric HIV infection

  1998cited by this paper
• Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

  1998cited by this paper
• Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance

  1997cited by this paper
• Maternal, Fetal, and Neonatal Physiology: A Clinical Perspective

  1992cited by this paper

• PKRxiv: A Best Practice Model for Advancing Pharmacoequity Through Open Pharmacokinetic Data Sharing.

  2026cites this paper
• An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens

  2025cites this paper
• Antiretroviral‐Induced Toxicity in Umbilical Cord Blood‐Derived Haematopoietic Stem/Progenitor Cells

  2025cites this paper
• Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis

  2025cites this paper
• Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women

  2025influential citation
• Effectiveness of dolutegravir based antiretroviral treatment in preventing vertical transmission of HIV in West Bengal, India: A retrospective cohort study

  2025cites this paper
• Maternal HIV Infection and Antiretroviral Therapy in Pregnancy: Implications for Vertical Transmission, Fetal Safety, and Long-Term Infant Outcomes

  2025cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling in the Research of Anti-HIV Drugs.

  2025cites this paper
• CEST MRI detects antiretroviral drug toxicities in the developing mouse brain

  2025cites this paper
• Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study

  2025influential citation
• The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study

  2025cites this paper
• Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps

  2024cites this paper
• Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review

  2024cites this paper
• Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review

  2024cites this paper
• Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development

  2024cites this paper
• Care of Pregnant Women Living with Human Immunodeficiency Virus.

  2024cites this paper
• Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

  2024cites this paper
• Current opinion: antiretrovirals during pregnancy and breastfeeding

  2024cites this paper
• Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis

  2024cites this paper
• Enhancing Precision Drug Therapy and build Pharmacokinetic model in Pregnant Women: PBPK Modeling of Antiviral drugs

  2024cites this paper
• Breakthrough HIV viraemia on bictegravir/emtricitabine/tenofovir alafenamide in the third trimester of pregnancy.

  2024cites this paper
• Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum

  2024cites this paper
• Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women

  2024cites this paper
• Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

  2024cites this paper
• Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature

  2024cites this paper
• Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy.

  2023cites this paper
• Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital

  2023cites this paper
• Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model

  2023influential citation
• Development and validation of an HPLC method for quantification of dolutegravir in human plasma.

  2023cites this paper
• Haematopoietic stem-cell transplantation in an HIV endemic area: time to consider donors exposed to or living with HIV.

  2023cites this paper
• Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy

  2023cites this paper
• A Systematic Review on Cardiometabolic Risks and Perinatal Outcomes among Pregnant Women Living with HIV in the Era of Antiretroviral Therapy

  2023cites this paper
• Translating Clinical Pharmacology Data in Pregnancy to Evidence‐Based Guideline Recommendations: Perspectives From the HIV Field

  2023cites this paper
• Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation

  2023cites this paper
• Congenital malformations and preeclampsia associated with integrase inhibitor use in pregnancy: A single-center analysis

  2023cites this paper
• Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir

  2023cites this paper
• Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors

  2023cites this paper
• HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment

  2022influential citation
• Tuberculosis Infection in Pregnant People: Current Practices and Research Priorities

  2022cites this paper
• UK guideline for the use of HIV post‐exposure prophylaxis 2021

  2022cites this paper
• Pharmacokinetic data in pregnancy: A review of available literature data and important considerations in collecting clinical data

  2022cites this paper
• Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review

  2022cites this paper
• Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: A review.

  2022cites this paper
• Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV

  2022cites this paper
• Integrase Inhibitors Use for HIV Infection in Pregnancy

  2022cites this paper
• Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir

  2021cites this paper
• HIV in pregnancy: mother-to-child transmission, pharmacotherapy, and toxicity.

  2021cites this paper
• Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment

  2021cites this paper
• Dolutegravir impairs stem cell-based 3D morphogenesis models in a manner dependent on dose and timing of exposure: an implication for its developmental toxicity.

  2021cites this paper
• Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester

  2021cites this paper
• Pharmacokinetics and placental transfer of dolutegravir in pregnancy.

  2021cites this paper
• Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots

  2021cites this paper
• Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation

  2021cites this paper
• Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development

  2021cites this paper
• Dolutegravir

  2021cites this paper
• Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

  2020cites this paper
• The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.

  2020cites this paper
• Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B Response and Central Memory CD4 T Cells

  2020cites this paper
• Clinical lactation studies and the role of pharmacokinetic modeling and simulation in predicting drug exposures in breastfed infants

  2020cites this paper
• Therapeutic drug monitoring of HIV antiretroviral drugs in pregnancy: A narrative review.

  2020cites this paper
• HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

  2020cites this paper
• Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

  2020cites this paper
• Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels

  2020cites this paper
• Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models

  2020cites this paper
• Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1

  2020cites this paper
• Effectiveness and safety of integrase inhibitors in HIV-infected pregnant women followed up in the Madrid Cohort

  2020cites this paper
• Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

  2020cites this paper
• Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

  2020cites this paper
• Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.

  2020cites this paper
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

  2020cites this paper
• Pharmacokinetics of HIV therapies in pregnant patients: an update

  2020cites this paper
• Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria

  2020cites this paper
• Model‐Informed Dose Optimization in Pregnancy

  2020cites this paper
• Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen

  2019cites this paper
• Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A#_#x00A0;randomised trial (DolPHIN-1 study)

  2019cites this paper
• The inhibitory effect of antiretroviral drugs on the L‐carnitine uptake in human placenta

  2019cites this paper
• Update on HIV integrase inhibitors for the treatment of HIV-1 infection

  2019cites this paper
• Adverse effects of using dolutegravir HIV in pregnant women and their newborn

  2019cites this paper
• Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling

  2019cites this paper
• Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.

  2019cites this paper
• Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.

  2019cites this paper
• Déjà vu all over again.

  2019cites this paper
• Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

  2019cites this paper
• Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

  2019cites this paper
• Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report

  2019cites this paper
• Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.

  2019cites this paper
• Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV

  2019cites this paper
• Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

  2018influential citation
• Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.

  2018cites this paper
• Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

  2018cites this paper
• Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing‐optimization study of current HIV antiretroviral regimens

  2018cites this paper
• State‐of‐the‐Art Review of HIV‐TB Coinfection in Special Populations

  2018cites this paper
• Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings.

  2018cites this paper
• Evaluating outcomes of mother–infant pairs using dolutegravir for HIV treatment during pregnancy

  2018cites this paper
• Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum

  year unknowncites this paper